,

Oncothermia EHY-2000: Latest technology

Oncothermia EHY-2000: Latest technology

Oncological Nanothermia or Oncothermia is a non-invasive modulated electromagnetic hyperthermia method, adjuvant in cancer treatment, which promotes a natural regulatory process of the body.

The Oncotherm® brand was founded in 1988 by Professor Dr. András Szász, as an initiative for the development and research of the electro-hyperthermia method in cancer treatment.

Oncothermia treatment began in Germany 25 years ago, and is currently used in more than 25 countries. It is important to note that in Germany alone equipment has been installed in 4 hospitals and in more than 50 clinics working effectively. In addition, each year more than 100,000 treatments are performed worldwide.

The latest generation model in Oncothermia is: EHY-2000. Currently there are other models of devices, but they do not guarantee the results obtained and investigated by Dr. András Szász.

At the Barcelona Oncothermia Unit you will find the latest technology to offer you the best results.

Scientific publications: Oncothermia journal

Scientific publications: Oncothermia journal

Knowledge is a common good that must be shared and placed at the service of society. That is why scientific publications are an important dissemination tool. Paying special attention to treatments as particular as Oncothermia.

Oncological Nanotherapy or Oncothermia is a treatment known and accepted by many oncological specialists and institutions. And of which there are numerous clinical and observational studies in European and international hospitals, with proven and published results. All of them can be consulted in Oncothermia Journal. The articles can be found in electronic or printed version

More information

Also, if you need more information about clinical studies or other publications related to Oncothermia, you can visit the following link, where you will find an extensive list of them.

Oncothermia in combination with Radiotherapy exerts a radiosensitizing effect in lung cancer.

efecto radiosensibilizante en el Cáncer de PulmónOncothermia in combination with Radiotherapy exerts a radiosensitizing effect in lung cancer.

The sensitivity of tumors to radiotherapy and chemotherapy is increased by Oncothermia.

Oncothermia, also known as electro-hyperthermia, is a new treatment modality that allows for increased sensitivity to other treatments. It has been developed to overcome the problems of traditional hyperthermia by targeting malignant tissues.

A study was published in 2015 in the journal Experimental and Therapeutic Medicine. It reports the outcome of combined oncothermia and RT in a 75-year-old patient with stage IIIB non-small-cell lung cancer (NSCLC).

Due to the advanced age and the performance status of the patient, the combination of systemic chemotherapy and RT was deemed infeasible. Therefore, the patient instead decided to undergo oncothermia concurrently with definitive RT.

The RT was administered at a dose of 64.8 Gy in 36 fractions using a three-dimensional conformal plan technique. In this case, Oncothermia was started concomitantly with RT. And was performed for 60 min per session, two sessions per week, for a total of 12 sessions.

Follow-up computed tomography showed complete tumor response. And the patient was alive with no evidence of the disease 18 months after the completion of the treatment.

In conclusion, the present case report suggests that oncothermia combined with RT has former possessing radiosensitizing potential and no additional toxicities. May be it is a promising alternative for advanced-age and/or frail patients with locally advanced NSCLC.

In addition, you can find more information about lung cancer on our website.

Transcranial Oncothermia in patients with relapsed high-grade gliomas

Glioma cáncer de cerebro

Transcranial Oncothermia in patients with relapsed high-grade gliomas

Experimental data and retrospective studies suggest potential effects

Dr. Wismeth’s Team of the Department of Neurology of the University of Regensburg, Germany, published in the journal J Neurooncol (J Neurooncol, 2010 Jul; 98 (3): 395-405) the results of the joint use of Oncothermia and chemotherapy used as salvage treatment in the relapse of patients with high-grade gliomas.

Experimental data and retrospective studies suggest potential effects. However, no prospective clinical results are available. A single-center prospective non-controlled single-arm Phase I trial was performed. Main inclusion criteria were recurrent high-grade glioma WHO Grade III or IV, age 18-70, and Karnofsky performance score > or = 70.

Primary endpoints were dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) with the combined regimen. Groups of 3 or 4 patients were treated 2-5 times a week in a dose-escalation scheme with Oncothermia. Alkylating chemotherapy (ACNU, nimustin) was administered at a dose of 90 mg/m(2) on day 1 of 42 days for up to six cycles or until tumor progression (PD) or DLT occurred. Fifteen patients with high-grade gliomas were included.

Relevant toxicities were local pain and increased focal neurological signs or intracranial pressure. No DLT occurred. In some patients, the administration of mannitol during EHT or long-term use of corticosteroids was necessary to resolve symptoms.

Results

Oncothermia in combination with chemotherapy is tolerable in patients with relapse of high-grade gliomas. A Phase II trial targeting treatment effects is warranted on the basis of the results raised in this trial.

If you wish, you can find more information about clinical cases treated with Oncotermia on our website.

Retrospective study of Oncothermia combined with chemotherapy for the treatment of Glioblastoma. Efficiency and cost-effectiveness analysis

Retrospective study of Oncothermia combined with chemotherapy for the treatment of Glioblastoma. Efficiency and cost-effectiveness analysis

Dr. Roussakow`s Team, Department Galenic Research Institute, Moscow, Russia, recently published in the Biomedical Journal Open (BMJ Open, 2017 Nov 3; 7 (11)) the results on the complementary use of Oncothermia in Glioblastoma multiform.

Researchers compared the efficacy and cost-effectiveness of Oncothermia (electrohyperthermia mEHT) with chemotherapy (temozolomide, ddTMZ) versus chemotherapy alone in a patient with recurrent Glioblastoma multiforme (GBM).

This is a retrospective study of a population of 54 patients diagnosed with recurrent Glioblastoma multiforme treated with chemotherapy and Oncothermia (ddTMZ + mEHT) during the period 2000-2005. The comparison was made with a population of 114 patients, diagnosed with GBM, treated with chemotherapy alone (ddTMZ) during the period 2008-2013.

Results:

The treatment effect analysis (ETA) suggests that Oncothermia significantly improves the survival of patients receiving oral chemotherapy (ddTMZ). Economic evaluation suggests that ddTMZ+Oncothermia is cost-effective, budget-saving and profitable. It is derived from the results that Oncothermia can be recommended for the treatment of recurrent Glioblastoma multiforme. Oncothermia can even be assessed as monotherapy as a rescue treatment when chemotherapy fails.

Synergy of Oncothermia with Vitamin C in the treatment of lung cancer

Dr Ou’s team, from Cancer Center, Clifford Hospital, Guangzhou, University of Medicine, China, published in the journal Eur J Pharm Sci. 2017 Nov 15; 109: 412-418, results on the synergy of intravenous Vitamin C and Oncothermia.

Vitamin C intravenously (VitC) and Oncothermia (electrohyperthermia modulated (mEHT)) have been used in medical centers for integrative medicine for the treatment of cancer, for many years. However, no pharmacokinetic study had been planned to assess Chinese cancer patients.

A clinical trial was conducted to evaluate safety and pharmacokinetics in patients with stage III-IV non-small cell lung cancer (NSCLC). A total of 35 patients with lung cancer (NSCLC) were included. A total of 15 patients with stage III-IV who entered the phase I study were selected. They were randomized allocated into 3 groups, and received doses 1.0, 1.2, 1.5 g/kg AA infusions. Participants in the first group received intravenous AA (IVAA) when mEHT was finished, in the second group IVAA was administered simultaneously with mEHT and in the third group IVAA was applied first, and followed with mEHT. The process was applied 3 times a week (every other day, weekend days off) for 4 weeks. We found that fasting plasma AA levels were significantly correlated with stage of the disease. Peak concentration of AA was significantly higher in the simultaneous treatments than in other combinations with mEHT or in solely IVAA-managed groups. 

Results:

IVAA synergy with simultaneous mEHT is safe. The concomitant application significantly increases the plasma AA level for NSCLC patients wiht non-small cell lung cancer (NSCLC).

Oncothermia Barcelona unit: latest generation model EHY-2000 plus

Oncothermia is a method of non-invasive modulated electromagnetic hyperthermia, complementary in the treatment against cancer, which promotes a natural regulatory process of the body. The brand Oncotherm® was founded in 1988 by Professor Dr. András Szász, as an initiative for the development and research of the electro-hyperthermia method in the treatment of cancer.

Treatment with Oncothermia started in Germany 25 years ago, and is currently used in more than 25 countries. Only in Germany is it in 4 hospitals and in more than 50 clinics functioning effectively. Every year more than 100,000 annual treatments are carried out worldwide

At the Oncothermia Barcelona Unit is the latest generation model: EHY-2000 plus, the latest technology to offer the best results

Modelo EHY-2000 de Oncothermia

About Oncothermia:

  • Oncothermia is active in all solid tumors.
  • No side effects, rare contraindications.
  • Energy absorption combined with modulated electric field.
  • Tumor tissue is treated selectively by destroying only the malignant tissue
  • Healthy tissue is not affected.
  • The effectiveness of chemotherapy and radiotherapy improves with treatment.
  • Restores intercellular junctions, suppresses dissemination (metastasis).
  • Oncothermia induces immunogenic cell death.
  • It improves the quality of life, reduces the side effects of other treatments.
  • A proven method for 30 years with more than 100,000 treatments per year.

Oncothermia in brain tumors

Prof. Giammaria Fiorentini of the Department of Onco-Hematology of Azienda Ospedaliera Marche Nord, Pesaro, Italy, presented at the 35th Annual Conference of the International Clinical Hyperthermia Society (ICHS) in Guangzhou, the results of their work in the treatment with Hyperthermia (Oncothermia) in patients with brain tumors.

The study was carried out with an Oncotherm EHY-2000 PLUS device, on 24 patients: 19 with glioblastoma multiforme and 5 with astrocytoma. All of them were previously treated with surgery, TMZ chemotherapy and radiotherapy.

Through the article Prof. Giammaria Fiorentini describes the characteristics of brain tumors, their incidence and mortality, survival and conventional therapies that are used, with an emphasis on the case of Glioblastoma and the benefits obtained by applying Electro-hyperthermia.

According to his observations Oncothermia (Electro-hyperthermia) is a non-invasive treatment, without toxicity and feasible to treat recurrent malignant gliomas, which allows to increase the response to the tumor and the survival of the patient.

The full article can be accessed by visiting this link.

Hypothesis: Studies that observe the effectiveness of Hyperthermia in HG Gliomas.

Oncothermia (Electro – Hyperthermia) traslational studies.

Oncothermia application in malignant gliomas.

Study on the activity and toxicity of Oncothermia in recurrent malignant gliomas.

Description of the equipment used: Oncotherm EHY-2000 PLUS, non-ionizing therapy that elevates the temperature of the tumor macro and micro-enviroments, to a range of 40-45ºC, generating a 40-150 Watt radiofrequency, at 13.56 MHz.

24 patients, 19 with glioblastoma multiforme and 5 with astrocytoma. All patient were pre-treated with surgery, chemotherapy and radiotherapy.

Oncothermia treatment: 3 sessions/week for 4 weeks, 20 a 60 minutes each session.

Results: 2 complete remissions and 5 partial remissions were observed. The medial OS was 14 months for gliomas and 61 months for astrocitomas.

Conclussions:

– Oncothermia applicated in patients with relapsed malignant gliomas is feasible and may increase tumor response and survival.

– EHT is a non-invasive method to treat malignant gliomas without toxicity.

– EHT appears to have effectiveness and further studies are warranted.

– EHT can be considered a landmark stone of integrative oncology.

Source:

Fiorentini G. (2018): Oncothermia in brain tumours; Oncothermia Journal 22: 151-177

www.oncothermia- journal.com/journal/2018/Oncothermia_in_brain_tumours.pdf

Clinical case: brain tumor, glioblastoma

CLINICAL CASE 5:

• BRAIN TUMOR (GLIOBLASTOMA)
• CHEMOTHERAPY + ONCOTHERMIA

A 60-year-old male presented a brain tumor in the left hemisphere in April 2016, showing the biopsy a high-grade glioblastoma multiforme inoperable by size. In July 2016 begins radiotherapy and chemotherapy with temozolamide coinciding with significant clinical worsening, tumor progression and increase in the number of epileptic seizures with more than 7 episodes a day. The patient had a significant decrease in the state of consciousness, total aphasia and right hemiparesis. Given the significant deterioration suffered by the treatment and tumor progression, evicted and without therapeutic options, the family rejects palliative treatment of chemotherapy and decide to perform treatment with oncothermia. In September 2016, she started treatment with oncothermia 60 minutes, 2-3 times / week continuously with some rest periods until March 2018. Throughout the treatment he has shown clinical improvement with improvement of aphasia and coordination. Until March 2018 without tumor progression.

Effects of the addition of electro-hyperthermia (Oncothermia) to chemoradiotherapy in cancer of the cervix. Randomized clinical trial – Phase III.

Dr. Minara CA of the University of Witwatersrand, Johannesburg, South Africa has published in the journal Oncothermia journal 21:56 57, 2017 an update on the phase III randomized clinical trial investigating the effects of the addition of electrons hyperthermia to chemoradiotherapy for patients with cancer of the cervix in South Africa.

The electrohyperthermia (EHT) trial is an ongoing phase III randomized clinical trial that is conducted at the Charlotte Maxeke Johannesburg Academic Hospital. The overall objective is to determine the clinical effects of the addition of modulated electrohyperthermia (EHT) to standard treatment protocols for locally advanced cervical cancer patients in state health care in South Africa. The objectives are to evaluate the effects of the addition of EHT on local control of the disease, quality of life, acute and late toxicity and overall survival.

Methods:

The purpose of the study is to treat 236 women with a FIGO IIB to IIIB stage of cervical cancer. Participants are randomly assigned to a group of “Hyperthermia” (EHT plus chemoradiation) and a group of “Control” (chemoradiation alone), strata of randomization: HIV status; years; stage of the disease. All participants receive external radiation of 50 Gy, 3 doses of brachytherapy with a high dose rate of 8 Gy and cisplatin. The “Oncothermia” group receives two local EHT treatments of 55 minutes per week during radiation therapy. Local control of the disease is evaluated by positron emission tomography (PET) scans. Adverse events, quality of life and overall survival are recorded and the data analyzed.

Results:

The first 100 participants are evaluated until they reach 6 months after treatment.

There has been a positive trend in the survival and local control of the disease in the group receiving OT.

There are no significant differences in acute adverse events or quality of life between the two groups.

The preliminary results of the addition of EHT are positive without impact on adverse events, however, this should be confirmed with more patients at the end of the study.